Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook (Q37316009)

19 August 2017

1 reference

title

Cutaneous delivery of prophylactic and therapeutic vaccines: historical perspective and future outlook (English)

1 reference

19 August 2017

1 reference

John A Mikszta

1

1 reference

PubMed ID

18980537

19 August 2017

Philippe E Laurent

series ordinal

2

1 reference

PubMed ID

18980537

19 August 2017

language of work or name

1 reference

1 November 2008

1 reference

Expert Review of Vaccines

19 August 2017

1 reference

19 August 2017

7

1 reference

19 August 2017

9

1 reference

19 August 2017

1329-1339

1 reference

Cutaneous vaccination: the skin as an immunologically active tissue and the challenge of antigen delivery

19 August 2017

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Changing paradigms in cutaneous immunology: adapting with dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Dendritic-cell trafficking to lymph nodes through lymphatic vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Intradermal hepatitis B vaccination in health care workers. Response rate and experiences from vaccination in clinical practise

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

The anti-HBs response after 2 different accelerated intradermal and intramuscular schemes for hepatitis B vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Comparison of higher-dose intradermal hepatitis B vaccination to standard intramuscular vaccination of healthcare workers

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Low-dose intradermal administration of recombinant hepatitis B vaccine in children: 5-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Intradermal recombinant hepatitis B vaccine for healthcare workers who fail to respond to intramuscular vaccine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Hepatitis B revaccination in healthy non-responder Chinese children: five-year follow-up of immune response and immunologic memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Failure of a reinforced triple course of hepatitis B vaccination in patients transplanted for HBV-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Efficacy and side effects of intradermal hepatitis B vaccination in CAPD patients: a comparison with the intramuscular vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Meta-analysis: intradermal vs. intramuscular vaccination against hepatitis B virus in patients with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Complete success of intradermal vaccination against hepatitis B in advanced chronic renal failure and hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Intradermal administration of viral vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

A vaccination strategy to enhance mucosal and systemic antibody and T cell responses against influenza.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Antibody responses after dose-sparing intradermal influenza vaccination.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Comparative immunogenicity of trivalent influenza vaccine administered by intradermal or intramuscular route in healthy adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Intradermal influenza vaccine administered using a new microinjection system produces superior immunogenicity in elderly adults: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Immunopharmacologic analysis of an autologous, hapten-modified human melanoma vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Successful induction of immune responses against mutant ras in melanoma patients using intradermal injection of peptides and GM-CSF as adjuvant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Granulocyte-macrophage colony-stimulating factor gene-modified autologous tumor vaccines in non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a phase 1 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Cellular and humoral immune response to N-Glycolyl-GM3 elicited by prolonged immunotherapy with an anti-idiotypic vaccine in high-risk and metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Immuno-gene therapy of cancer with tumour-mRNA transfected dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Experience with heat shock protein-peptide complex 96 vaccine therapy in patients with indolent non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Phase I trial of a novel intradermal idiotype vaccine in patients with advanced B-cell lymphoma: specific immune responses despite profound immunosuppression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Vaccination with Ep-CAM protein or anti-idiotypic antibody induces Th1-biased response against MHC class I- and II-restricted Ep-CAM epitopes in colorectal carcinoma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Transcutaneous immunization with heat-labile enterotoxin: development of a needle-free vaccine patch

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Effect of skin barrier disruption on immune responses to topically applied cross-reacting material, CRM(197), of diphtheria toxin

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Topical immunization using nanoengineered genetic vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Vesicular carrier constructs for topical immunisation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Safety and immunogenicity of an enterotoxigenic Escherichia coli vaccine patch containing heat-labile toxin: use of skin pretreatment to disrupt the stratum corneum

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Cutaneous delivery of a live, attenuated chimeric flavivirus vaccine against Japanese encephalitis (ChimeriVax)-JE) in non-human primates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Improved genetic immunization via micromechanical disruption of skin-barrier function and targeted epidermal delivery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Protective immunization against inhalational anthrax: a comparison of minimally invasive delivery platforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Microneedles permit transdermal delivery of a skin-impermeant medication to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Microneedles for transdermal drug delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Low-frequency ultrasound as a transcutaneous immunization adjuvant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Transdermal delivery of macromolecules by erbium:YAG laser

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Erbium:YAG laser-mediated oligonucleotide and DNA delivery via the skin: an animal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Controlled removal of human stratum corneum by pulsed laser

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Use of a patch containing heat-labile toxin from Escherichia coli against travellers' diarrhoea: a phase II, randomised, double-blind, placebo-controlled field trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Needle-free liquid jet injections: mechanisms and applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Epidermal powder immunization against influenza

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

A model to assess the infection potential of jet injectors used in mass immunisation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Coated microneedles for transdermal delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Effect of delivery parameters on immunization to ovalbumin following intracutaneous administration by a coated microneedle array patch system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Coating formulations for microneedles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Sugar micro needles as transdermic drug delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Minimally invasive protein delivery with rapidly dissolving polymer microneedles

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Evaluation of the clinical performance of a new intradermal vaccine administration technique and associated delivery system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Preclinical Evaluation of Microneedle Technology for Intradermal Delivery of Influenza Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Microneedle-based intradermal delivery of the anthrax recombinant protective antigen vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Echographic measurement of skin thickness in adults by high frequency ultrasound to assess the appropriate microneedle length for intradermal delivery of vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Intradermal hepatitis B vaccination in patients with advanced chronic renal failure: immunogenicity and follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Economic evaluation of strategies for the control and management of influenza in Europe

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

Induction of specific T cell immunity in patients with prostate cancer by vaccination with PSA146-154 peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14760584.7.9.1329

10.1586/14760584.7.9.1329

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

18980537